Special Drug Use-results Survey for Long-term Administration of Invega 3mg/6mg/9mg Tablet
Not Applicable
- Conditions
- Schizophrenia
- Registration Number
- JPRN-UMIN000015599
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1350
Inclusion Criteria
Not provided
Exclusion Criteria
NA
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sefety(Adverse Drug Reaction) Effectiveness(Clinical Global Impression-Schizophrenia)
- Secondary Outcome Measures
Name Time Method Effectiveness(Social and Occupational Functioning Assessment Scale)